未来的方向和矿物质皮质皮质体受体对手治疗的创新
Shashank Joshi1, Mangesh Tiwaskar2, Jayanta Sharma3
1Consultant Endocrinologist, Department of Diabetology and Endocrinology, Lilavati Hospital and Research Center, Mumbai, Maharashtra, India, Corresponding Author.
The Journal of the Association of Physicians of India
|March 12, 2026
概括
矿物质皮质类受体抗剂 (MRA) 是治疗心力衰竭和脏疾病的关键. 结合SGLT2i和GLP-1RAs的组合疗法在心血管-脏-代谢综合征方面显示出更好的结果.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
背景情况:
- 矿物质皮质类受体抗剂 (MRA) 是心力衰竭 (HF),慢性病 (CKD) 和糖尿病病 (DKD) 的已确立治疗方法.
- 在心血管--代谢 (CKM) 综合征中,MRAs与-葡萄糖共运输体2抑制剂 (SGLT2i) 和葡萄糖类-1受体激动剂 (GLP-1RAs) 作用于互补的途径.
- 阿尔多斯特和矿物质皮质类受体 (MR) 通过MRAs的对抗作用对于管理各种疾病至关重要.
研究的目的:
- 突出MRA在CKM综合征治疗中的作用.
- 探索涉及MRAs,SGLT2i和GLP-1RAs的组合疗法的好处.
- 讨论MRA特定生物标志物的个人化医学潜力.
主要方法:
- 对MRA,SGLT2i和GLP-1RA疗法的现有文献的审查.
- 对CKM综合征的补充途径和组合治疗结果的分析.
- 对MRA治疗个性化的生物标志物效用 (UACR,eGFR) 的检查.
主要成果:
- 与SGLT2i和GLP-1RA结合的MRA组合疗法在CKM综合征中表现出优异的结果,与单一疗法相比.
- 由于其独特的作用机制,MRA在正在进行的临床试验中显示出前景.
- 疾病特异性生物标志物如UACR和eGFR越来越多地用于个性化MRA治疗.
结论:
- 涉及MRAs,SGLT2i和GLP-1RAs的组合疗法代表了对CKM综合征的有希望的策略.
- 对MRA特异性生物标志物的进一步研究可以在心血管和病管理中推进精准医学.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:30Heart Failure V: Medical Management
459
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
459
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
2.5K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.5K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K